Search





Search





Markets
/
Stocks
/
nasdaq-nvcr
/

Novocure Ltd

NVCR

Add to Watchlist

17.580USD

-0.470-2.60%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

2.04BMarket Cap

LossP/E TTM



Novocure Ltd

17.580

-0.470-2.60%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Novocure Ltd

Currency: USD Updated: 2026-05-15

Key Insights

Novocure Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.29.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Novocure Ltd's Score

Industry at a Glance

Industry Ranking

47 / 206

Overall Ranking

127 / 4482

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Novocure Ltd Highlights

StrengthsRisks

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 28.67% year-on-year.

Fairly Valued

The company’s latest PE is -11.46, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 99.30M shares, decreasing 10.29% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 71.08K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

26.286

Target Price

+45.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Novocure Ltd is 6.57, ranking 137 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 174.06M, representing a year-over-year increase of 12.30%, while its net profit experienced a year-over-year increase of 107.28%.

Score

Industry at a Glance

Previous score

6.57

Change



Financials

5.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.34

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.33

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Novocure Ltd's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Novocure Ltd is 7.00, ranking 132 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -11.46, which is -47.84% below the recent high of -5.98 and -1072.63% above the recent low of -134.38.

Score

Industry at a Glance

Previous score

7.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/206

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Novocure Ltd is 8.00, ranking 66 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 24.00, with a high of 42.00 and a low of 14.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

26.286

Target Price

+45.63%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

116

Total

Median

Average

Company name

Ratings

Analysts

Novocure Ltd

NVCR

Medtronic PLC

MDT

Stryker Corp

SYK

Zimmer Biomet Holdings Inc

ZBH

Abbott Laboratories

ABT

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Novocure Ltd is 9.39, ranking 6 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 20.46 and the support level at 13.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.47

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.439

Buy

RSI(14)

68.326

Neutral

STOCH(KDJ)(9,3,3)

70.642

Sell

ATR(14)

1.137

High Vlolatility

CCI(14)

60.444

Neutral

Williams %R

18.331

Overbought

TRIX(12,20)

1.971

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

18.028

Sell

MA10

17.416

Buy

MA20

15.275

Buy

MA50

13.094

Buy

MA100

12.947

Buy

MA200

12.729

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Novocure Ltd is 7.00, ranking 80 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 85.75%, representing a quarter-over-quarter increase of 1.87%. The largest institutional shareholder is James Simons, holding a total of 1.39M shares, representing 1.20% of shares outstanding, with 73.78% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

16.80M

+0.16%

Soleus Capital Management, L.P.

8.53M

-11.55%

BlackRock Institutional Trust Company, N.A.

9.02M

+0.35%

Wyss (Hansjorg)

8.14M

Morgan Stanley & Co. LLC

3.24M

+399.74%

State Street Investment Management (US)

2.58M

-1.28%

Geode Capital Management, L.L.C.

2.48M

+0.07%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Novocure Ltd is 5.65, ranking 77 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.